Boehringer Ingelheim - Top 15 Pharma R&D Budgets

R&D budget: $3.03B (€2.21B)
Change over 08: +5%
Income spent on R&D: 17.4%

Big Pharma R&D budgets usually dwarf the estimated revenue expected from their experimental therapies. But Boehringer beat the spread just weeks ago when it delivered on its long-awaited approval of Pradaxa, a blood-thinner expected to go on to earn billions in annual sales revenue.

Boehringer has been active on the partnering side of the business, but it was a latecomer to the corporate venture game. Back in March the company announced plans to invest $137 million in biotech companies as it sent its scout teams around the world to find the most promising new developers on the scene.

Boehringer's top three disease focuses: Cardiovascular, respiratory and cerebrovascular diseases.

Boehringer Ingelheim - Top 15 Pharma R&D Budgets
Read more on

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.